At Neurostrat, our vision is to shape the future of drug discovery through artificial intelligence and machine learning solutions that turn biomedical complexity into therapeutic clarity.
In the last two decades, there has been a massive accumulation of genetic data, but the clinical interpretation of many genetic variants, particularly in neurodegenerative diseases, remains limited. Neurodegenerative diseases are currently the second leading cause of death.
Despite discovering numerous variants, no existing database focuses on Variants of Uncertain Significance (VUS) specifically linked to neurodegenerative diseases.
As a result, many patients receive ineffective treatments due to poor stratification, leading to unnecessary suffering, failed clinical trials, and delayed access to effective therapies.
The annual cost of neurodegenerative diseases to the EU healthcare system is €800 billion. In addition, pharmaceutical companies face substantial financial losses due to high clinical trial failure rates and increasing research and development expenses.
There is an urgent and growing need for better tools to enable precision medicine approaches in the field of neurodegeneration
Portfolio Valuation & Reporting: Maintain accurate financial statements with real-time crypto asset valuations.
NEUROSTRAT will enable better patient stratification by utilizing genomic data to match patients with effective treatments. This will support clinical decision-making, contributing to improved treatment outcomes and reduced adverse effects. NEUROSTRAT will accelerate the discovery and validation of novel biomarkers for neurodegenerative diseases.
NEUROSTRAT innovation will help optimize healthcare costs, improve clinical trials' success rates, and significantly shorten the time-to-market for new therapies by providing earlier and more accurate targeting of treatments.
NEUROSTRAT is an innovative clinical software platform designed to transform the management of neurodegenerative diseases by providing advanced patient stratification tools.
The NEUROSTRAT platform has reached Technology Readiness Level 5 (TRL5), having been successfully validated with real-world clinical and genomic data.
In collaboration with Heidelberg University Hospital, NEUROSTRAT was applied to a real clinical case of chordoma (Case 1), a rare and inoperable bone cancer. In partnership with major pharmaceutical company, NEUROSTRAT was used to stratify 500 patients with Multiple Sclerosis (MS) based purely on clinical parameters (Case 2).
enables the stratification of patients using only clinical data, such as symptom profiles, disease progression, and diagnostic results.
enables the stratification of patients using only clinical data, such as symptom profiles, disease progression, and diagnostic results.
combines clinical and genomic data, mapping variants to biological pathways and therapeutic targets, enabling precise identification of disease mechanisms and treatment opportunities.
NEUROSTRAT technology corresponds to the TRL5 because it was tested in a relevant environment and functionally validated in a realistic clinical context. It showed:
the ability to propose effective personalized treatments, including off-label options;
the potential to anticipate resistance mechanisms;
the integration within a real clinical decision-making process, confirming functional validation in situ;
the ability to integrate and analyse multidimensional clinical and molecular data from actual patients;
an unbiased, data-driven stratification of patients that was considered more clinically;
downstream molecular correlation, leading to the identification of candidate biomarkers and mutation patterns.
Case 1 – 54-year-old patient suffering from chordoma.
NEUROSTRAT identified a molecular signature involving PARP1, suggesting a potential responsiveness to the PARP1 inhibitor.
Following the initiation of the treatment (initially self-funded by the patient), a positive response was observed, prompting the insurance provider to cover the therapy. After 18 months, a resistance mutation emerged. The NEUROSTRAT AI system was able to retrospectively match this mutation to a previously known resistance variant to the treatment.
Multiple Sclerosis (MS) Patient Stratification
The study focused on a cohort of 500 MS patients, with 295 completing the 96-week follow-up. Three types of data were collected: 79 clinical parameters, next-generation sequencing (NGS), and gene expression data. NEUROSTRAT performed unbiased patient stratification based on clinical parameters. NEUROSTRAT grouping method was confirmed to better reflect disease progression by clinical trial scientists. Molecular analysis was then correlated to these clinically-derived groups, allowing identification of potential biomarkers and genetic signatures associated with disease subtypes.
NEUROSTRAT has moved beyond laboratory testing: it has proven its functionality and clinical relevance through real patient cases, demonstrating a direct impact on therapeutic decision-making.
Steps toward TRL6:
formal clinical validation studies
expansion of the dataset to diverse neurodegenerative disease cohorts;
preparation for regulatory alignment and clinical deployment.
Multimodal Data Integration: NEUROSTRAT uniquely combines clinical observations, genomic sequencing data, and systems biology modeling into a unified patient stratification approach. Unlike conventional tools that rely solely on genetic or clinical information, NEUROSTRAT integrates these layers to identify biologically meaningful patient subgroups.
Mechanistic Modeling Framework: The platform employs proprietary probabilistic network models that map genetic variants to biological pathways, protein functions, and potential therapeutic targets. This mechanistic approach enables the functional interpretation of Variants of Uncertain Significance (VUS), a critical unmet need in neurodegenerative disease diagnostics.
Clinician-Friendly User Interface: NEUROSTRAT is designed specifically for non-bioinformaticians, offering an intuitive interface that allows clinicians to stratify patients without requiring deep computational expertise.
Multimodal Data Integration: NEUROSTRAT uniquely combines clinical observations, genomic sequencing data, and systems biology modeling into a unified patient stratification approach. Unlike conventional tools that rely solely on genetic or clinical information, NEUROSTRAT integrates these layers to identify biologically meaningful patient subgroups.
Modular and Scalable Architecture: Each tool (Clinical Strata, Genomic Strata, Mechanistic Strata) can be used independently or as an integrated solution, making the platform highly adaptable to different clinical and research environments.
Software-as-a-Service (SaaS) Deployment: NEUROSTRAT is delivered as a cloud-based service, ensuring that the core algorithms, analytical pipelines, and mechanistic models remain secure and inaccessible to external users. This protects the proprietary technology as a trade secret under EU and international IP frameworks.
Patent Strategy: Key innovative components — including the mechanistic network analysis module and VUS ranking methodology — are currently being assessed for patentability. Filing strategic patents will enhance the competitive positioning of NEUROSTRAT and provide additional protection for critical technology assets.
Data Sovereignty Compliance: NEUROSTRAT ensures full GDPR compliance by maintaining patient data within European servers, reinforcing trust with healthcare providers and clinical partners. By combining proprietary technology, trade secret protection, and targeted patenting, NEUROSTRAT builds a robust intellectual property position to sustain its long-term market advantage.
Gordana has 20+ year of experience in chief executive roles of technology companies in the area of pharmaceutical R&D. She is expert with a proven scientific track record in the biomarker area, data and knowledge management solutions, safety assessment and bioinformatics. Gordana leads the company over the last 15 years.
Tomasz is experienced software developer. He has been in the area of industrial bioinformatics in two companies over the last 20 years. He worked on several FP6/7 and HORIZON 2020 large collaborative projects. Tomasz is expert in database development, bioinformatics tools design and data visualization techniques
Tamara has 15+ years experience in sales and business development, negotiations in B2B with multinational companies (pharma, cosmetics), marketing, market analysis and competitive intelligence.
The global market for neurodegenerative disease treatments was valued at $59.06 billion in 2025, and it is expected to reach $83.37 billion by 2030, growing at a CAGR of 7.14%. Pharmaceutical companies typically allocate around 20% of revenue to R&D, which translates into $11.8 billion annually for neurodegenerative disease-related research. Of this, an estimated 10–15% is relevant to patient stratification tools, representing a Total Addressable Market (TAM) of approximately $1.2–1.8 billion.
Serviceable Available Market (SAM)
Focusing on the US and EU markets (80% of global R&D expenditure), SAM is around $960 million to $1.44 billion. Serviceable Obtainable Market (SOM): Realistically targeting 0.5% of the SAM, our SOM is projected to be around €4.8–7.2 million.
Initial Beachhead Market
European pharmaceutical companies and research hospitals specializing in neurodegenerative diseases. Early adopters in the UK, Germany, Italy, and the Netherlands with active NGS and precision medicine programs.
Unique Selling Proposition (USP)
NEUROSTRAT is the first clinical platform integrating clinical data, genomic data, and mechanistic systems biology to stratify patients with neurodegenerative diseases, with a particular focus on Variants of Uncertain Significance (VUS).Unlike existing tools, NEUROSTRAT is designed for real-world clinical use, accessible even to non-bioinformatics experts.
COMPETITIVE ADVANTAGES
Technical
Multimodal data integration (clinical + genomic + mechanistic).
Proprietary AI-based mechanistic network modeling for variant interpretation.
Focus on VUS, a major gap not addressed by other platforms.
Commercial
SaaS model tailored for hospitals and pharmaceutical companies.
Easy clinical adoption through intuitive user interfaces.
Scalability for use across multiple neurodegenerative diseases.
During the scale-up phase, CNET expects revenues to grow significantly. Starting from approximately €215,270 in 2025 (excluding revenues from the EICA product line), the total revenue is projected to reach €5.35 million by 2031, once EICA is fully commercialized.
The company anticipates that sales of EICA will begin in 2027 with 4 units sold, and will expand to 186 units by 2031. At the same time, sales of other products (non-EICA) are expected to grow from 35 units in 2024 to 167 units in 2031. EBITDA is projected to remain negative until 2029 due to upfront investment needs, but becomes positive in 2030 at €150,000 and reaches €4.5 million by 2031, marking a transition to a highly profitable phase.
EIC Accelerator Support
We are requesting a total grant of €2.3 million. The majority of the budget (€1.9 million) will cover personnel costs to recruit and retain a multidisciplinary team. We plan to invest €200,000 in essential infrastructure(computing equipment, software licenses, and in-house AI servers). A further €150,000 is allocated for travel and networking, and €50,000 will support dissemination and communication to maximize the project’s impact and visibility.
Use of Funds
The equity funding of €8.5 million will support activities essential for scaling and market entry. This includes continuing R&D activities beyond the grant phase, supporting regulatory and clinical validation efforts, and scaling commercial activities. These funds will also be used to strengthen the team and engage early adopters through targeted commercial strategies. The EIC Accelerator’s blended financing model is uniquely suited to de-risk this project and ensure its success, as it allows early validation with grant funding, while ensuring continuity and scale-up through equity support.
EIC Grant
Clinical validation studies (TRL6 → TRL8).
Regulatory approval processes (CE marking).
Market access preparation and pilot deployments in partner hospitals.
Investment Component
Commercial scale-up (sales team expansion, international distribution).
Further product development (expanding to other diseases beyond neurodegeneration).
Key Elements of the Business Model
CNET is developing a new core business branch centered on patient stratification in neurodegenerative diseases, complementing its established toxicology services. The new business is anchored in the FUTURA platform, composed of three modular software tools for genomic and mechanistic patient stratification. These tools can be sold individually or bundled as a full solution. The value proposition lies in enabling pharmaceutical companies, hospitals, and research centers to stratify patients more effectively, optimize clinical trial outcomes, and support precision medicine.
Unit Economics
Customer price per analysis: ~€50
Estimated unit cost (per platform/software use): ~€3,914
Gross margin: grows with volume due to fixed cost amortization (R&D, validation, infra)
Revenue Projections (Selected Years)
2025: €215,270 (from existing scientific services, databases, and tool licenses).
2027: EICA product sales begin with 4 units, scaling to 186 units by 2031.
2029: revenue exceeds €1.6 million
2031: CNET enters a highly profitable phase.
Breakeven Point
Projected by 2029, with EBITDA turning positive (~€150K) and scaling to €4.5 million by 2030.
NEUROSTRAT bridges the gap between genomics, clinical data, and real-world decision-making, delivering precision medicine where it matters most — in neurodegenerative diseases.
Our multidisciplinary team — with proven expertise in bioinformatics, clinical research, and business scaling — has already validated NEUROSTRAT in real clinical environments, and is ready to lead its full-scale deployment.
Protected by a strong IP strategy and built on a clinically tested platform, NEUROSTRAT is positioned to become the European benchmark for patient stratification in the €800B neurodegenerative disease healthcare sector.
The equity funding of €8.5 million will support activities essential for scaling and market entry. This includes continuing R&D activities beyond the grant phase, supporting regulatory and clinical validation efforts, and scaling commercial activities. These funds will also be used to strengthen the team and engage early adopters through targeted commercial strategies. The EIC Accelerator’s blended financing model is uniquely suited to de-risk this project and ensure its success, as it allows early validation with grant funding, while ensuring continuity and scale-up through equity support.Innovation Development CoverageThe EIC grant will cover:Clinical validation and final development of Product 3Regulatory compliance and technical refinement (TRL 6 → TRL 8)Personnel costs, infrastructure, networking, and disseminationThe investment component will cover:Scaling of commercial operations and market deploymentExpansion into new markets and partnerships (BRL 5 → BRL 8)Continued R&D, team growth, and go-to-market strategy execution.